Correlation Engine 2.0
Clear Search sequence regions

  • humans (1)
  • hydrogen ion (1)
  • patient (1)
  • prodrug (11)
  • tumor sites (1)
  • Sizes of these terms reflect their relevance to your search.

    The rapid development of nanotechnology results in the emergence of nanomedicines, but the effective delivery of drugs to tumor sites remains a great challenge. Prodrug-based cancer nanomedicines thus emerged due to their unique advantages, including high drug load efficiency, reduced side effects, efficient targeting, and real-time controllability. A distinctive characteristic of prodrug-based nanomedicines is that they need to be activated by a stimulus or multi-stimulus to produce an anti-tumor effect. A better understanding of various responsive approaches could allow researchers to perceive the mechanism of prodrug-based nanomedicines effectively and further optimize their design strategy. In this review, we highlight the stimuli-responsive pathway of prodrug-based nanomedicines and their anticancer applications. Furthermore, various types of prodrug-based nanomedicines, recent progress and prospects of stimuli-responsive prodrug-based nanomedicines and patient data in the clinical application are also summarized. Additionally, the current development and future challenges of prodrug-based nanomedicines are discussed. We expect that this review will be valuable for readers to gain a deeper understanding of the structure and development of prodrug-based cancer nanomedicines to design rational and effective drugs for clinical use. Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.


    Angel Xie, Sumaira Hanif, Jiang Ouyang, Zhongmin Tang, Na Kong, Na Yoon Kim, Baowen Qi, Dylan Patel, Bingyang Shi, Wei Tao. Stimuli-responsive prodrug-based cancer nanomedicine. EBioMedicine. 2020 Jun;56:102821

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 32505922

    View Full Text